Viridian Therapeutics, Inc. $VRDN Stock Position Decreased by JPMorgan Chase & Co.

Key Points

• JPMorgan cut its Viridian stake by 25.7% in Q3, selling 106,856 shares and leaving it with 309,133 shares (about 0.32% of the company, valued at $6.67 million).
• Viridian announced positive Phase‑3 REVEAL‑1 topline results that met the primary endpoint, but the stock experienced a volatile reaction—plunging over 30% in early trading while several analysts trimmed price targets; the consensus rating remains a "Moderate Buy" with a $39.21 target.
• Despite JPMorgan's reduction and near‑term volatility, multiple institutions (notably Commodore, Wellington and Fisher) substantially increased their VRDN positions, indicating continued institutional interest.

JPMorgan Chase & Co. lowered its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 25.7% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 309,133 shares of the company's stock after selling 106,856 shares during the period. JPMorgan Chase & Co. owned about 0.32% of Viridian Therapeutics worth $6,671,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of VRDN. Commodore Capital LP raised its position in shares of Viridian Therapeutics by 35.4% during the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company's stock worth $68,152,000 after buying an additional 1,275,000 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Viridian Therapeutics by 314.9% in the third quarter. Wellington Management Group LLP now owns 1,122,532 shares of the company's stock valued at $24,224,000 after acquiring an additional 851,989 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of Viridian Therapeutics by 135.6% during the third quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company's stock valued at $25,922,000 after acquiring an additional 691,267 shares during the period. Rice Hall James & Associates LLC raised its holdings in Viridian Therapeutics by 65.2% during the third quarter. Rice Hall James & Associates LLC now owns 851,663 shares of the company's stock worth $18,379,000 after purchasing an additional 336,040 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Viridian Therapeutics by 33.8% during the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company's stock worth $16,595,000 after purchasing an additional 310,998 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on VRDN. The Goldman Sachs Group decreased their price target on Viridian Therapeutics from $41.00 to $36.00 and set a "buy" rating for the company in a research note on Tuesday. Evercore reissued an "outperform" rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 20th. Wedbush cut their price objective on Viridian Therapeutics from $44.00 to $37.00 and set an "outperform" rating for the company in a report on Tuesday. William Blair assumed coverage on Viridian Therapeutics in a research note on Wednesday, December 3rd. They set an "outperform" rating for the company. Finally, Wells Fargo & Company lowered their target price on Viridian Therapeutics from $29.00 to $20.00 and set an "equal weight" rating on the stock in a report on Tuesday. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $39.21.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 hit its primary endpoint: elegrobart produced statistically significant proptosis responder rates (Q4W 54%, Q8W 63% vs placebo 18%) — an important clinical validation that supports a potential approval path. Business Wire release
• Positive Sentiment: Multiple outlets reported the positive topline data (press coverage that confirms the readout and its details may help downstream regulatory and partnering discussions). Las Vegas Sun article
• Positive Sentiment: Some sell‑side firms remain constructive despite cuts — Goldman Sachs cut its target to $36 but kept a "buy" rating, Wedbush cut to $37 and kept "outperform", and Needham trimmed to $32 while retaining "buy" — these keep a material upside narrative for investors who focus on longer‑term commercial potential. Benzinga
• Neutral Sentiment: Market commentary and audio/newscasts are covering the swing (podcast coverage and “stocks to watch” lists) — reflects heightened attention but does not add new clinical or financial data. Bloomberg podcast
• Neutral Sentiment: News aggregators and analysts explain the paradox: the trial met its primary endpoint but market expectations for effect size, secondary endpoints, safety, dosing, or commercial assumptions may not have been met — this discussion is driving intraday volatility. Seeking Alpha
• Negative Sentiment: Several analysts trimmed price targets and/or lowered ratings: Wells Fargo cut target to $20 and moved to "equal weight", HC Wainwright cut to $22 (still "buy") — these downward revisions compress near‑term upside and signal more conservative commercial or launch assumptions. Benzinga
• Negative Sentiment: Despite positive topline data, the stock plunged (>30% in earlier trading) on investor disappointment and profit‑taking; coverage highlighting the selloff and "stock tumbles despite trial success" may amplify short‑term selling pressure. Investing.com

Viridian Therapeutics Trading Up 5.6%

Shares of NASDAQ VRDN opened at $19.56 on Wednesday. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $34.29. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -5.95 and a beta of 1.00. The business has a fifty day simple moving average of $29.16 and a 200-day simple moving average of $27.89.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $15.75 million. Sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.